Respiratory Virus News and Research

RSS

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19, the coronavirus disease of 2019, is one of the worst pandemics in human history. It emerged in December 2019 and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nearly 164 million SARS-CoV-2 infections and 3.4 million deaths have been reported globally since the beginning of the pandemic, which is still raging in many countries.

18 May 2021

COVID-19 public health interventions reduced other respiratory infections

Wearing masks and quarantining while sick has helped mitigate the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). An indirect benefit of these efforts appears to be a decrease in flu cases and other respiratory infections. New research led by Lisa G. Winston of the University of California, San Francisco, confirmed COVID-19 public health interventions helped decrease the number of airborne viruses.

18 May 2021

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Scientists at the University of Zurich have modified a common respiratory virus, called adenovirus, to act like a Trojan horse to deliver genes for cancer therapeutics directly into tumor cells. Unlike chemotherapy or radiotherapy, this approach does no harm to normal healthy cells.

18 May 2021

Nanotechnology and COVID-19 diagnosis and treatment

The development of nano-biosensors and nanoparticle-based vaccines and medicines has opened a new path toward better management of the coronavirus disease 2019 (COVID-19) pandemic. In a recently published article in the journal ACS Biomaterials Science & Engineering, scientists have reviewed recent advancements in nanotechnology-based diagnostic and therapeutic interventions against human coronaviruses.

17 May 2021

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

Researchers at UC Santa Cruz have developed a novel chip-based antigen test that can provide ultrasensitive detection of SARS-CoV-2 and influenza A, the viruses that cause COVID-19 and flu, respectively.

12 May 2021

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

Researchers in the United States and Austria have demonstrated the potential of a modified influenza virus as a vaccine to protect against viral respiratory pathogens, including the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

2 May 2021

COVID-19 survivors have increased risk of death for at least six months

As the COVID-19 pandemic has progressed, it has become clear that many survivors - even those who had mild cases - continue to manage a variety of health problems long after the initial infection should have resolved.

23 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

A new preprint research paper posted to the medRxiv* server explores the antibody response to COVID-19 vaccines in elderly residents of nursing homes in the USA. As of March 2021, there have been over 1.4 million infections from SARS-CoV-2 and over 175,000 deaths related to the pandemic among nursing home residents in the country.

13 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

Scientists identify nine potential new COVID-19 treatments

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

2 Apr 2021

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

Researchers tested the nasopharyngeal microbiome of children up to 21 years old and found the microbiome changes with age. Specific bacteria, whose abundance also changes with age, are associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection susceptibility and severity.

25 Mar 2021

COVID-19 prevention strategies may have led to a decrease in common respiratory infections

Wearing masks and physical distancing - two key infection prevention strategies implemented to stop the spread of COVID-19 - may have led to the dramatic decrease in rates of common respiratory viral infections, such as influenza.

23 Mar 2021

Can SARS-CoV-2 still be transmissible once symptoms have subsided?

Researchers based at the University of Missouri, in partnership with U.S. government science facilities in Maryland, have reported that individuals severely infected with SARS-CoV-2 may be able to continue shedding infectious viral RNA for over three weeks after the symptomatic infection has passed.

22 Mar 2021

Living with a COVID-19 case brings worse symptoms and stronger antibody response

This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.

17 Mar 2021

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

The currently developed vaccines against SARS-CoV-2 include the RBD in their immunogen. With a similar objective, a new study developed an RBD protein-based vaccine candidate against the SARS-CoV-2, using self-assembling Helicobacter pylori-bullfrog ferritin nanoparticles as an antigen delivery system. The study is published recently in the journal mBio (by the American Society of Microbiology).

8 Mar 2021

Rapid point-of-care test used to diagnose respiratory infections can reduce antibiotic prescribing

A rapid microbiological point-of-care test to diagnose respiratory infections has proved popular with GPs and could reduce antibiotic prescribing in primary care, according to a National Institute for Health Research funded study by researchers at the Centre for Academic Primary Care, University of Bristol.

4 Mar 2021

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

A new study compares the pathogenicity and infectiousness of one such variant, the VOC 202012/01 (B.1.1.7 lineage) from the United Kingdom, with the globally dominant D614G mutation-carrying strains.

2 Mar 2021

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

As scientists continue to search for effective antidotes to direct and indirect damage caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv* server demonstrates the potential of cannabinoid receptor agonists to alleviate myocardial damage in this condition even in the absence of any inhibitory effect on viral infection as such.

23 Feb 2021

Endothelial SARS-CoV-2 infection induces proinflammatory responses without supporting viral amplification, finds study

A team of scientists from Australia and Brazil recently investigated the involvement of endothelial cells in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

18 Feb 2021

Respiratory Virus News and Research

SARS-CoV-2 mRNA vaccine PTX-COVID19-B safe and highly immunogenic in preclinical study

COVID-19 public health interventions reduced other respiratory infections

New technology tricks tumors to eliminate itself through the production of anti-cancer agents

Nanotechnology and COVID-19 diagnosis and treatment

Novel chip-based antigen test can provide ultrasensitive detection of SARS-CoV-2, influenza A

Live "attenuated" influenza virus vaccine protects animals against respiratory infections, including SARS-CoV-2

COVID-19 survivors have increased risk of death for at least six months

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Measurable antibody response to mRNA COVID-19 vaccine in elderly care home residents

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

Scientists identify nine potential new COVID-19 treatments

Changing upper respiratory microbiome in children related to SARS-CoV-2 susceptibility

COVID-19 prevention strategies may have led to a decrease in common respiratory infections

Can SARS-CoV-2 still be transmissible once symptoms have subsided?

Living with a COVID-19 case brings worse symptoms and stronger antibody response

Self-assembling nanoparticles an effective vaccine candidate for SARS-CoV-2

Rapid point-of-care test used to diagnose respiratory infections can reduce antibiotic prescribing

SARS-CoV-2 UK variant shows low virulence and high shedding in hamster model

Cannabinoid receptor agonist shows potential protective effect on SARS-CoV-2-infected human heart cells

Endothelial SARS-CoV-2 infection induces proinflammatory responses without supporting viral amplification, finds study

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News